Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study

Levetiracetam (LEV) monotherapy was investigated in 25 patients with advanced Alzheimer's disease (AD) and new-onset epileptic seizures in a prospective open-label study. At a daily dose of 1000–1500 mg, 72% were seizure-free for at least one year; 16% discontinued for untolerability; 8% were unresponsive; 4% were lost to follow-up. These results suggest the need for controlled studies to confirm if LEV can be a first-choice drug in AD.     

原发性高血压患者应用抗高血压药物不良事件原因分析

目的 探讨原发性高血压患者应用抗高血压药物不良事件及其原因。方法 将243例观察对象按照用药正确与否分3组，应用面对面横断面调查方法，分析比较组间不良事件发生率及其原因。结果 导致原发性高血压患者发生不良事件的主要原因是经常停药、他人介绍用药、媒介宣传用药、经济原因停药、配伍不合理、测量值不正确、用一种药物时间过长和药物个体适应性差等原因。结论 合理正确应用抗高血压药物对于保护高血压患者靶器官具有重要意义。     

骨松宝胶囊治疗老年人胸腰椎压缩性骨折疗效分析

微创球囊扩张椎体后凸成形术,是治疗老年骨质疏松脊柱压缩骨折安全有效的方法[1]。然而,由于经济的问题以及观念的影响,大量的老年患者还是选择了保守治疗的方式。针对这类患者,我们寻求有效合理的药物,以达到缩短病程、早期康复的目的,发现采用保守治疗的同时辅以中成药骨松宝     

The anti-inflammatory profile of fluticasone propionate

Fluticasone propionate is a new corticosteroid based on the androstane nucleus. It is more lipophilic than beclomethasone dipropionate (BDP) and budesonide, and binds more avidly to human lung tissue. It has an absolute affinity (K_D) of 0.5 nM for the glucocorticoid receptor and a relative receptor aflinity 1.5- and 3.0-times greater than that of beclomethasone-17-monopropionate (17-BMP) and budesonide, respectively. The rate of association with the receptor is faster and the rate of dissociation slower than with standard corticosteroids. As a result, the half-life of the corticosteroid-receptor complex is >10 h. Fluticasone propionate is also highly selective for the glucocorticoid receptor, with little or no activity at other steroid receptors. Pretreatment with fluticasone propionate signiflcantly inhibits the increase in mast cell numbers in the nasal mucosa of rats chronically exposed to toluene di-isocyanate (TDI), and suppresses TDI-induced mast cell degranulation. It is more potent in vitro than dexamethasone, BDP and budesonide in inhibiting anti-CD3-induced human T-lymphocyte proliferation, in attenuating tumour necrosis factor-α-induced endothelial cell adhesion molecule expression, and in increasing secretory leucocyte protease inhibitor levels in airway epithelial cells. It is also more potent and longer-acting than other corticosteroids in inhibiting oedema formation, interleukin-5 (IL-5)-induced blood eosinophilia, and IL-5- or platelet activating factor-stimulated eosinophil accumulation in the lung. Fluticasone propionate therefore has increased intrinsic glucocorticoid potency and high topical anti-inflammatory activity.     

Cholinergic therapy in dementia

After reviewing the evidence for cholinergic pathology in Alzheimer's disease and related disorders, this paper reviews strategies for treating dementia using cholinomimetic drugs. Special attention is paid to cholinesterase inhibitors, particularly tacrine, the drug recently approved by the FDA. New studies suggesting that muscarinic and nicotinic cholinergic receptor active drugs may be more effective will be reviewed. Brief mention will be made of strategies to slow the progression of Alzheimer's disease.     

Critical review of treatment trials in hypertension

Summary: Despite numerous deficiencies in some antihypertensive drug treatment trials, and some questionable selections of studies for inclusion in several meta-analyses, undoubtedly such trials have shown treatment benefits from reducing hypertension. Complications that can be corrected or prevented include malignant hypertension, hypertensive heart failure, stroke and coronary artery morbidity. the all-cause mortality has been lowered in several trials. the benefits have been seen in subjects aged over 60 years, in women and men, and in patients with isolated systolic hypertension. the benefits have been achieved using a wide range of drugs, not only with beta-blockers or diuretics. Non-pharmacological means of lowering blood pressure have not been evaluated in relation to morbidity.     

不同时程给予抗精神病药物对大鼠脑内AchE活性的影响

目的 探索常敏和超敏状态时乙酰胆碱酯酶活性的变化及该变化与锥体外系症状（ＥＰＳ）的可能关系。方法 应用分光光度法测定大鼠脑皮层、海马和纹状体ＡｃｈＥ催化碘化乙酰硫代胆碱水解的速率而确定酶的活性。结果 急性给予利血平、氯氮平、氟哌啶醇对大鼠纹状体、海马和皮层的ＡｃｈＥ活性无显著影响；以相同剂得的利血平、氯氮平和氟哌啶醇连续给药７ｄ和２１ｄ，利血平和氟哌啶醇显著降低纹状体和海马ＡｃｈＥ活性，氯氮平仅在     

空管药物疗法治疗牙髓病和根尖周病疗效观察

用ＳＭＴＤ复合药物对牙髓病和根尖周病实施空管药物疗法。７８例１０３颗获得完整随访资料患牙经两年观察，９２．２％治愈率。文章介绍了治疗方法，讨论了空管药物疗法的愈合机理、优点、失败原因及其预防措施。     

Psychotropic drug intake in residents newly admitted to nursing homes

While several surveys have shown that psychotropic drugs are frequently used by nursing home residents, no studies have been performed to investigate whether the rates of drug use increase during the stay in nursing homes or whether residents have taken these drugs already before admission. Therefore, we investigated 262 residents admitted to rural and urban nursing homes in Austria for prevalence of psychotropic drug intake before admission, shortly after admission, and 6 months later. Two weeks after admission, 72.1% of the residents were being treated with psychotropics, while 6 months later 79.0% were receiving these drugs. The significantly higher rates of psychotropic drug use among the psychiatrically ill and in those suffering from sleeping problems suggest that these drugs were prescribed aptly, but residents without appropriate criteria for drug intake were often also treated with psychotropics. During 3 months before admission to nursing homes, 45.5% of the sample reported having taken psychotropics. In more than half of residents without drug intake before admission, psychotropic treatment was initiated within the first 2 weeks after admission, while during the first 6 months after admission the rate of drug use increased only slightly. This suggests that a large percentage of psychotropic intake is due to nursing home orders. Received: 20 January 1997/Final version: 21 May 1997